GlobeNewsWire
27 Apr 2026, 21:37 UTC · 24w ago
Verdict
Headline takes no side. We score BMEA +0.90 — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
Which stocks this story touches
More positive than 96% of ticker scores this week
The company announced positive Phase 2 trial results for icovamenib in type 1 diabetes patients, showing unprecedented improvement in insulin secretion.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1d ago
−27.2%
Price is moving against the score
$1.26 vs $1.73 close before publication (Apr 27) · not market-adjusted
BMEA chart →
